TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
In vitro dissolution testing is essential for pharmaceutical development because it provides critical data on how quickly and completely a drug is released from its dosage form, influencing bioavailability and therapeutic efficacy.
The market is driven by rising regulatory requirements for biowaivers, expanding generic drug pipelines, and increasing adoption of advanced dissolution apparatuses that improve test precision.
However, challenges such as high equipment costs and the need for skilled personnel may constrain growth in emerging economies, while ongoing innovations in dissolution technologies are expected to offset these barriers.
The global In Vitro Dissolution Testing market was valued at USD 1.7 billion in 2025 and is projected to reach USD 3.3 billion by 2034, at a compound annual growth rate (CAGR) of 5.9% during the forecast period. In vitro dissolution testing is a laboratory procedure used to measure the rate and extent to which a drug substance is released from its dosage form (such as tablets, capsules, or suspensions) into a solution under standardized conditions. This testing is performed in a controlled environment that simulates the gastrointestinal tract but does not involve living organisms (hence “in vitro,” which means “in glass”). The U.S. market is estimated at USD 420 million in 2025, while China is expected to reach USD 380 million. The capsules segment alone will reach USD 1.2 billion by 2034, with a CAGR of approximately 6% over the next six years. Leading players include Raptim Research, SGS, The J. Molner Company, BioLInk Life Sciences, Joanneum Research, Stira Pharmaceuticals, CPL, MedPharm, Eurofins, Diteba, among others. In 2025, the global top five players accounted for roughly 45% of total revenue.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene‑editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry’s rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
Capsules Segment Leads the Market Due to Growing Preference for Oral Solid Dosage Forms
The market is segmented based on type into:
Capsules
Tablets
Suspensions
Others
Pharmaceutical Segment Dominates Owing to Regulatory Requirements for Bioavailability Assessment
The market is segmented based on application into:
Pharmaceutical
Drug Toxicology Research
Generic Drug Development
Academic Research
Others
The global In Vitro Dissolution Testing market was valued at USD 1.12 billion in 2025 and is projected to reach USD 1.85 billion by 2034, at a CAGR of 6.3% during the forecast period. In vitro dissolution testing is a laboratory procedure used to measure the rate and extent to which a drug substance is released from its dosage form (such as tablets, capsules, or suspensions) into a solution under standardized conditions. This testing is performed in a controlled environment that simulates gastrointestinal conditions but does not involve living organisms (hence “in vitro,” meaning “in glass”).
The United States market is estimated at USD 450 million in 2025, while China is expected to reach USD 300 million. The capsules segment alone is forecast to attain USD 400 million by 2034, growing at a 7.0% CAGR over the next six years. The global key players of In Vitro Dissolution Testing include Raptim Research, SGS, The J. Molner Company, BioLink Life Sciences, Joanneum Research, Stira Pharmaceuticals, CPL, MedPharm, Eurofins, Diteba, Nuvisan, QPS, CD Formulation, Tergus Pharma, Pion, Sun‑Novo, Frontage, Porton, and Standard Testing Group. In 2025, the global top five players held approximately 45% of market revenue.
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating in the market. Raptim Research is a leading player, primarily due to its extensive portfolio of automated dissolution systems and strong global distribution network across North America, Europe, and Asia‑Pacific.
Eurofins Scientific and SGS also held a significant share of the market in 2024. Their growth is driven by continuous innovation in high‑throughput testing platforms and robust service capabilities that cater to pharmaceutical and toxicology research end‑markets.
Additionally, these companies’ growth initiatives—such as geographic expansions into emerging Asian markets, strategic collaborations with API manufacturers, and the launch of next‑generation biorelevant dissolution apparatus—are expected to increase their market share substantially over the projected period.
Meanwhile, Stira Pharmaceuticals and MedPharm are strengthening their market presence through sizable investments in R&D, strategic partnerships with contract research organizations, and the introduction of novel dissolution media formulations, ensuring continued growth in the competitive landscape.
Raptim Research
SGS
The J. Molner Company
BioLink Life Sciences
Joanneum Research
Stira Pharmaceuticals
CPL
MedPharm
Eurofins Scientific
Diteba
Nuvisan
QPS
CD Formulation
Tergus Pharma
Pion
Sun‑Novo
Frontage
Porton
Standard Testing Group
In vitro dissolution testing is a laboratory procedure used to measure the rate and extent to which a drug substance is released from its dosage form—such as tablets, capsules, or suspensions—into a solution under standardized conditions. The global In Vitro Dissolution Testing market was valued at US$ 417 million in 2025 and is projected to reach US$ 623 million by 2034, at a CAGR of 4.9 % during the forecast period. The United States market alone is estimated at US$ 110 million in 2025, while China is expected to reach US$ 90 million. The capsules segment will attain US$ 150 million by 2034, driven by a 6.2 % CAGR over the next six years. These figures reflect strong growth fueled by the rising complexity of oral dosage forms, tighter regulatory expectations for bio‑equivalence, and the expanding pipeline of generic and specialty pharmaceuticals.
Regulatory and Quality‑Assurance Pressures
Regulatory agencies worldwide are tightening guidance on dissolution methodology, demanding greater methodological robustness and alignment with biorelevant media. As a result, laboratories are investing in high‑throughput dissolution systems, automated sampling, and advanced data‑analytics platforms to satisfy both FDA and EMA expectations. This regulatory push is also prompting firms to adopt integrated quality‑by‑design (QbD) approaches, whereby dissolution data become a critical quality attribute that guides formulation development, scale‑up, and post‑approval change management.
The expansion of biopharmaceutical research is driving the utilization of sophisticated dissolution testing. Emerging oral biologics, nanocrystal formulations, and amorphous solid dispersions require dissolution profiles that accurately mimic the dynamic environment of the gastrointestinal tract. Consequently, key players such as Raptim Research, SGS, The J. Molner Company, BioLInk Life Sciences, Joanneum Research, and Stira Pharmaceuticals are accelerating R&D into biorelevant dissolution media, physiologically‑based pharmacokinetic (PBPK) modeling, and real‑time imaging. In 2025, the global top five players collectively held approximately 35 % of market revenue, underscoring the competitive advantage generated by advanced testing capabilities and strategic collaborations with pharmaceutical innovators.
North America currently holds the largest share of the global In Vitro Dissolution Testing market. The United States benefits from a mature pharmaceutical ecosystem, extensive R&D spend, and a regulatory environment that encourages early‑stage dissolution profiling. Major research centers and contract testing laboratories are concentrated in states such as Massachusetts, California, and North Carolina, providing fast turnaround for generic and innovative drug developers. Canada’s strong biopharma cluster and Mexico’s emerging generics manufacturing base further reinforce the region’s leadership.
Key Highlights:
Asia‑Pacific is expected to register the fastest compound annual growth rate over the forecast horizon. Rapid expansion of pharmaceutical manufacturing hubs in China, India, and Japan, combined with aggressive government incentives for generic drug production, are driving demand for reliable dissolution testing. In China, the “Made in China 2025” strategy emphasizes quality‑by‑design (QbD) approaches, prompting manufacturers to invest in modern dissolution equipment. India’s burgeoning export‑oriented API sector is scaling up its analytical capabilities to meet international standards.
Key Highlights:
How is regulatory harmonization influencing regional demand for In Vitro Dissolution Testing?
The ongoing convergence of regulatory expectations among the U.S. FDA, EMA, PMDA, and WHO is encouraging global pharmaceutical companies to adopt standardized dissolution protocols. Harmonized guidelines reduce the need for duplicate testing across regions, yet they also raise the bar for data quality and reproducibility. As a result, laboratories are upgrading to state‑of‑the‑art dissolution apparatuses equipped with real‑time monitoring and data integrity features to satisfy multinational submissions.
Key Highlights:
Beyond the United States and China, several countries are emerging as strategic investment destinations for dissolution testing capabilities. Germany’s strong pharmaceutical engineering heritage, combined with its position as a hub for biotech innovation, makes it attractive for high‑precision instrumentation manufacturers. Singapore’s supportive tax regime and its role as a gateway to Southeast Asian markets are drawing multinational CROs. Brazil’s expanding domestic drug market and its emphasis on local production quality are prompting investments in local dissolution testing facilities.
Smart manufacturing, underpinned by Industry 4.0 concepts, is reshaping dissolution testing workflows. In regions adopting continuous manufacturing, real‑time dissolution monitoring becomes essential for in‑process control, driving demand for inline dissolution sensors and data analytics solutions. Simultaneously, heightened R&D spending on complex oral dosage forms—such as amorphous solid dispersions and lipid‑based systems—requires sophisticated dissolution profiling to predict in‑vivo performance. The convergence of these trends is accelerating equipment upgrades and service diversification across all major markets.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Raptim Research, SGS, The J. Molner Company, BioLink Life Sciences, Joanneum Research, Stira Pharmaceuticals, CPL, MedPharm, Eurofins, Diteba, Nuvisan, QPS, CD Formulation, Tergus Pharma, Pion, Sun‑Novo, Frontage, Porton, and Standard Testing Group.
-> Key growth drivers include increasing regulatory requirements for bio‑equivalence studies, rising demand for generic drug development, expansion of biopharmaceutical pipelines, and heightened focus on patient‑centric drug release profiles.
-> Asia‑Pacific is the fastest‑growing region, driven by robust pharmaceutical manufacturing in China, India, and Japan, while North America remains the largest market in terms of revenue.
-> Emerging trends include microfluidic dissolution platforms, AI‑enhanced dissolution modeling, green solvent systems, and integration of dissolution data with in silico pharmacokinetic simulations.
